These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 34050650)
21. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965 [TBL] [Abstract][Full Text] [Related]
22. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. Melchers MJ; Mavridou E; Seyedmousavi S; van Mil AC; Lagarde C; Mouton JW Antimicrob Agents Chemother; 2015; 59(6):3373-6. PubMed ID: 25824214 [TBL] [Abstract][Full Text] [Related]
23. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis. Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928 [TBL] [Abstract][Full Text] [Related]
24. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143 [TBL] [Abstract][Full Text] [Related]
25. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Wooley M; Miller B; Krishna G; Hershberger E; Chandorkar G Antimicrob Agents Chemother; 2014; 58(4):2249-55. PubMed ID: 24492369 [TBL] [Abstract][Full Text] [Related]
26. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620 [TBL] [Abstract][Full Text] [Related]
27. Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis. Winans SA; Guerrero-Wooley RL; Park SH; Hino G; Forland SC Infection; 2021 Apr; 49(2):355-359. PubMed ID: 32862306 [TBL] [Abstract][Full Text] [Related]
28. Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. Attwood M; Griffin P; Noel AR; Albur M; Macgowan AP J Antimicrob Chemother; 2023 Sep; 78(9):2254-2262. PubMed ID: 37527369 [TBL] [Abstract][Full Text] [Related]
29. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP. Gao W; Passarell J; Patel YT; Zhang Z; Lin G; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda CS; Feng HP Antimicrob Agents Chemother; 2022 May; 66(5):e0139921. PubMed ID: 35471040 [TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia. Zhang Z; Patel YT; Fiedler-Kelly J; Feng HP; Bruno CJ; Gao W J Clin Pharmacol; 2021 Feb; 61(2):254-268. PubMed ID: 32949031 [TBL] [Abstract][Full Text] [Related]
31. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741 [TBL] [Abstract][Full Text] [Related]
32. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579 [TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model. Melchers MJ; Mavridou E; van Mil AC; Lagarde C; Mouton JW Antimicrob Agents Chemother; 2016 Dec; 60(12):7272-7279. PubMed ID: 27671063 [TBL] [Abstract][Full Text] [Related]
34. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. Xiao AJ; Miller BW; Huntington JA; Nicolau DP J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377 [TBL] [Abstract][Full Text] [Related]
35. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection. Noel AR; Bowker KE; Attwood M; MacGowan AP J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472 [TBL] [Abstract][Full Text] [Related]
36. Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. Matzneller P; Ngougni Pokem P; Capron A; Lackner E; Wulkersdorfer B; Nussbaumer-Pröll A; Österreicher Z; Duchek M; Van de Velde S; Wallemacq PE; Mouton JW; Van Bambeke F; Zeitlinger M J Antimicrob Chemother; 2020 Sep; 75(9):2650-2656. PubMed ID: 32433753 [TBL] [Abstract][Full Text] [Related]
37. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. Shortridge D; Pfaller MA; Castanheira M; Flamm RK Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane. Vanscoy B; Mendes RE; McCauley J; Bhavnani SM; Bulik CC; Okusanya OO; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG Antimicrob Agents Chemother; 2013 Dec; 57(12):5924-30. PubMed ID: 24041895 [TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. Chandorkar G; Xiao A; Mouksassi MS; Hershberger E; Krishna G J Clin Pharmacol; 2015 Feb; 55(2):230-9. PubMed ID: 25196976 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]